Background Depression, anxiety and schizophrenia among older persons have become global public health challenges. However, the burden of these disorders in ageing and aged countries has not been analysed. Aims To investigate the burden of depression, anxiety and schizophrenia among older adults in ageing and aged countries. Methods Using data from the Global Burden of Disease Study 2019, we calculated the estimated annual percentage change (EAPC) in the age-standardised incidence rates (ASIR) and age-standardised disability-adjusted life years (DALYs) rates (ASDR) for depression, anxiety and schizophrenia of older people in ageing countries (China, India, Indonesia) and aged countries (Japan, Italy, Portugal) between 1990 and 2019. Trends in incidence and DALYs were analysed by gender and age. Results In 2019, the highest incidence of depression, anxiety and schizophrenia in the older population in aged countries was in Japan (927 271.3 (752 552.3–1 125 796.5), 51 498.2 (37 625.7–70 487.3) and 126.0 (61.0–223.2), respectively), while the highest incidence in ageing countries was in China (5 797 556.9 (4 599 403.4–7 133 006.5), 330 256.1 (246 448.9–445 987.4) and 1067.7 (556.2–1775.9), respectively). DALYs for these disorders were similar, with the highest in Japan and China. From 1990 to 2019, the ASIR for depressive disorders decreased in aged countries but increased in ageing countries; the ASIR for anxiety disorders and schizophrenia declined in both ageing and aged countries. The ASDR for depressive disorders was consistent with the ASIR but not for anxiety disorders and schizophrenia. The ASIR for depressive disorders was higher in older women, while the opposite was observed in anxiety disorders and schizophrenia. Notably, the conditions of burden of depressive disorders, anxiety disorders and schizophrenia in the 65–70-year-old age group were the most burdensome. Conclusions The incidence and DALYs of these three mental disorders increased while exhibiting differences between ageing and aged countries. Raising awareness about formulating health policies for preventing and treating mental disorders in the older population is necessary to reduce the future burden posed by the ageing challenge.

The period from childhood to early adulthood is critically susceptible to the onset of mental disorders (MDs), substance use disorders (SUDs), and self-harm, with significant implications for public health policy. Understanding these trends over time and across different regions is essential for effective intervention and resource allocation. This study utilizes data from GBD 2021, focusing on youths aged 10–24 years globally. Data span from 1990 to 2021, providing a longitudinal perspective on trends and are stratified by age groups, gender, geographic regions, and Socio-demographic Index (SDI). The results showed that in 2021, the global standardized prevalence of MDs among youths reached 14,778 per 100,000, marking a 6.8%(4.7–9.0) increase from 1990. Anxiety disorders and depressive disorders exhibited the highest prevalence. The prevalence of SUDs decreased by 20.3%(17.4–22.9) since 1990, while self-harm rates decreased by 35%(33.6–38.3). The highest burden was observed in the 20–24 age group, with notable gender disparities: females had higher rates of anxiety and depressive disorders, whereas males were more affected by SUDs and conduct disorders. Geographical and socio-economic variations were pronounced, with high SDI regions exhibiting the most significant prevalence of most MDs and SUDs. The study highlights a significant rise in the burden of MDs among global youth over three decades, exacerbated during the COVID-19 pandemic. It underscores the need for targeted mental health interventions and resource allocation to address the escalating mental health needs of young populations.

Chemotherapeutic agents can result in extravasation, which is considered to be a serious complication. The increasing number of exposures to different cytotoxic agents experienced by each patient may enhance the prevalence of this complication. Docetaxel is widely used in the treatment of numerous solid tumors. Thus, the current report presents the case of a breast cancer patient who developed a significantly delayed skin reaction one day after docetaxel extravasation, a rare skin manifestation, and relapsed one week subsequently. This unusual clinical presentation is an indicator that practitioners are required to carefully monitor the patient for further cutaneous reactions in the weeks following extravasation to observe any additional adverse reactions.